Effectiveness and Safety of JAK Inhibitors in Patients With Atopic Dermatitis Unresponsive Versus Naïve to Dupilumab: A Multicentric Real-World Retrospective Study

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F25%3A10503155" target="_blank" >RIV/00179906:_____/25:10503155 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/61988987:17110/25:A2603DK7 RIV/00216208:11110/25:10503155 RIV/00216208:11120/25:43928851 RIV/00216208:11130/25:10503155 a 10 dalších

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=Kor_Lt9P-t" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=Kor_Lt9P-t</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1155/dth/5548750" target="_blank" >10.1155/dth/5548750</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Effectiveness and Safety of JAK Inhibitors in Patients With Atopic Dermatitis Unresponsive Versus Naïve to Dupilumab: A Multicentric Real-World Retrospective Study

Popis výsledku v původním jazyce

Introduction: Janus kinase (JAK) inhibitors are novel therapies for atopic dermatitis (AD); however, only limited data exist on their effectiveness in patients with previous failures in biological treatment. Methods: Patients with moderate-to-severe AD and having completed a minimum of 16 weeks of JAK inhibitor therapy were divided into subgroups based on prior dupilumab exposure: those without prior exposure and those whose treatment was discontinued due to lack of efficacy (dupilumab nonresponders [DNR]). Eczema Area and Severity Index (EASI), DLQI, and Itch Numeric Rating Scale (Itch NRS) changes from baseline were assessed in Weeks 16 and 24 (when available). Adverse events during the follow-up were recorded. Results: In total, 241 patients were included; 148 received upadacitinib (99 dupilumab-naïve, 49 post-dupilumab failure), 47 were with baricitinib (32 dupilumab-naïve, 15 post-dupilumab failure), and 46 received abrocitinib (35 dupilumab-naïve, 11 post-dupilumab failure). At Week 16, an EASI-75 response in the upadacitinib group was achieved in 86% naïve versus 82% DNR patients, 91% naïve versus 73% DNR patients in the abrocitinib group, and 81% naïve versus 67% DNR in the baricitinib group. Itch NRS GREATER-THAN OR EQUAL TO 4-point reduction was achieved in 82% naïve versus 76% DNR patients on upadacitinib, 83% naïve versus 91% DNR patients on abrocitinib, and 72% naïve versus 40% DNR patients on baricitinib. Conclusion: In conclusion, our retrospective analysis suggests that previous dupilumab failure did not significantly affect the short-term effectiveness of JAK inhibitor therapy for AD.

Název v anglickém jazyce

Effectiveness and Safety of JAK Inhibitors in Patients With Atopic Dermatitis Unresponsive Versus Naïve to Dupilumab: A Multicentric Real-World Retrospective Study

Popis výsledku anglicky

Introduction: Janus kinase (JAK) inhibitors are novel therapies for atopic dermatitis (AD); however, only limited data exist on their effectiveness in patients with previous failures in biological treatment. Methods: Patients with moderate-to-severe AD and having completed a minimum of 16 weeks of JAK inhibitor therapy were divided into subgroups based on prior dupilumab exposure: those without prior exposure and those whose treatment was discontinued due to lack of efficacy (dupilumab nonresponders [DNR]). Eczema Area and Severity Index (EASI), DLQI, and Itch Numeric Rating Scale (Itch NRS) changes from baseline were assessed in Weeks 16 and 24 (when available). Adverse events during the follow-up were recorded. Results: In total, 241 patients were included; 148 received upadacitinib (99 dupilumab-naïve, 49 post-dupilumab failure), 47 were with baricitinib (32 dupilumab-naïve, 15 post-dupilumab failure), and 46 received abrocitinib (35 dupilumab-naïve, 11 post-dupilumab failure). At Week 16, an EASI-75 response in the upadacitinib group was achieved in 86% naïve versus 82% DNR patients, 91% naïve versus 73% DNR patients in the abrocitinib group, and 81% naïve versus 67% DNR in the baricitinib group. Itch NRS GREATER-THAN OR EQUAL TO 4-point reduction was achieved in 82% naïve versus 76% DNR patients on upadacitinib, 83% naïve versus 91% DNR patients on abrocitinib, and 72% naïve versus 40% DNR patients on baricitinib. Conclusion: In conclusion, our retrospective analysis suggests that previous dupilumab failure did not significantly affect the short-term effectiveness of JAK inhibitor therapy for AD.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30216 - Dermatology and venereal diseases

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Dermatologic Therapy

ISSN

1396-0296

e-ISSN

1529-8019

Svazek periodika

2025

Číslo periodika v rámci svazku

September

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

10

Strana od-do

5548750

Kód UT WoS článku

001575215100001

EID výsledku v databázi Scopus

2-s2.0-105016820079